{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:08:58Z","timestamp":1789193338379,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p xml:lang=\"en\">Secondary antibiotic prophylaxis with regular intramuscular benzathine penicillin G (BPG) is the cornerstone of rheumatic heart disease management. However, there is a growing body of evidence that patients with rheumatic heart disease who have severe valvular heart disease with or without reduced ventricular function may be dying from cardiovascular compromise following BPG injections. This advisory responds to these concerns and is intended to: (1) raise awareness, (2) provide risk stratification, and (3) provide strategies for risk reduction. Based on available evidence and expert opinion, we have divided patients into low\u2010 and elevated\u2010risk groups, based on symptoms and the severity of underlying heart disease. Patients with elevated risk include those with severe mitral stenosis, aortic stenosis, and aortic insuffiency; those with decreased left ventricular systolic dysfunction; and those with New York Heart Association class III and IV symptoms. For these patients, we believe the risk of adverse reaction to BPG, specifically cardiovascular compromise, may outweigh its theoretical benefit. For patients with elevated risk, we newly advise that oral prophylaxis should be strongly considered. In addition, we advocate for a multifaceted strategy for vasovagal risk reduction in all patients with rheumatic heart disease receiving BPG. As current guidelines recommend, all low\u2010risk patients without a history of penicillin allergy or anaphylaxis should continue to be prescribed BPG for secondary antibiotic prophylaxis. We publish this advisory in the hopes of saving lives and avoiding events that can have devastating effects on patient and clinician confidence in BPG.<\/jats:p>","DOI":"10.1161\/jaha.121.024517","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T08:54:47Z","timestamp":1642668887000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Penicillin Reactions in Patients With Severe Rheumatic Heart Disease: A Presidential Advisory From the American Heart Association"],"prefix":"10.1161","volume":"11","author":[{"given":"Amy","family":"Sanyahumbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sulafa","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivor J.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesan","family":"Karthikeyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmy","family":"Okello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig A.","family":"Sable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Taubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Wyber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesl","family":"Zuhlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Carapetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Z.","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the American Heart Association","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024769"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2013-303896"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gheart.2013.08.011"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.191959"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/heartasia-2019-011191"},{"key":"e_1_3_1_8_2","unstructured":"RHD Action. Global Status of BPG Report. 2016. Accessed October 23 2020. https:\/\/rhdaction.org\/sites\/default\/files\/RHD%20Action_Global%20Status%20of%20BPG%20Report_Online%20Version.pdf"},{"key":"e_1_3_1_9_2","volume-title":"Rheumatic Fever and Rheumatic Heart Disease","author":"World Health Organization","year":"2018","unstructured":"World Health Organization . WHO Technical Report Series 92. Vol 11:95:1\u20105. Rheumatic Fever and Rheumatic Heart Disease. 2018. Accessed December 16, 2021. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA71\/A71_25\u2010en.pdf"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1962.03050040042013"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00843"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.21037\/cdt.2018.12.09"},{"key":"e_1_3_1_13_2","first-page":"1308","article-title":"Allergic reactions to long\u2010term benzathine penicillin prophylaxis for rheumatic fever. International Rheumatic Fever Study Group","volume":"337","author":"Markowitz M","year":"1991","unstructured":"Markowitz M, Kaplan E, Cuttica R. Allergic reactions to long\u2010term benzathine penicillin prophylaxis for rheumatic fever. International Rheumatic Fever Study Group. Lancet. 1991;337:1308\u20131310.","journal-title":"Lancet"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1089\/088318700750070439"},{"key":"e_1_3_1_15_2","unstructured":"World Health Organization . WHO Pharmaceuticals Newsletter 2000 No. 04. Geneva Switzerland; 2000:22."},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/652239"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056463"},{"key":"e_1_3_1_18_2","volume-title":"Australian Immunisation Handbook","author":"Australian Technical Advisory Group on Immunisation (ATAGI)","year":"2018","unstructured":"Australian Technical Advisory Group on Immunisation (ATAGI) . Australian Immunisation Handbook. Australian Government Department of Health; 2018. Accessed September 15, 2020. immunisationhandbook.health.gov.au"},{"key":"e_1_3_1_19_2","first-page":"86","volume-title":"Acute Rheumatic Fever and Rheumatic Heart Disease","author":"Horton AG","year":"2020","unstructured":"Horton AG, Remenyi B. Clinical evaluation and management of rheumatic heart disease. In: Dougherty SC, Z\u00fchlke L, Wilson N, eds. Acute Rheumatic Fever and Rheumatic Heart Disease. Elsevier; 2020:86\u201396."},{"key":"e_1_3_1_20_2","first-page":"CD002227","article-title":"Penicillin for secondary prevention of rheumatic fever","volume":"2002","author":"Manyemba J","year":"2002","unstructured":"Manyemba J, Mayosi BM. Penicillin for secondary prevention of rheumatic fever. Cochrane Database Syst Rev. 2002;2002:CD002227. doi: 10.1002\/14651858.CD002227","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_1_21_2","unstructured":"Beggs S Peterson G Tompson A. Antibiotic use for the prevention and treatment of rheumatic fever and rheumatic heart disease in children. Report for the 2nd Meeting of World Health Organization\u2019s subcommittee of the Expert Committee of the Selection and Use of Essential Medicines; 2008. Accessed December 15 2021. https:\/\/www.who.int\/selection_medicines\/committees\/subcommittee\/2\/RheumaticFever_review.pdf"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/cir.0000000000000031"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-0508"},{"key":"e_1_3_1_24_2","volume-title":"The 2020 Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease (3rd Edition)","year":"2020","unstructured":"RHDAustralia (ARF\/RHD writing group). The 2020 Australian Guideline for Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease (3rd Edition). RHD Australia; 2020."},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)99015-3"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1042\/cs1000335"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03426.x"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02574.x"},{"key":"e_1_3_1_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02189.x"},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03202.x"},{"key":"e_1_3_1_31_2","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/17-136"},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-097X.2005.00642.x"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-009-9114-7"},{"key":"e_1_3_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(90)90134-5"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.5830\/CVJA-2019-042"},{"key":"e_1_3_1_36_2","volume-title":"Rheumatic fever and rheumatic heart disease","author":"World Health Organization Study Group on Rheumatic Fever and Rheumatic Heart Disease","year":"2001","unstructured":"World Health Organization Study Group on Rheumatic Fever and Rheumatic Heart Disease . WHO Technical Report Series 923. Rheumatic fever and rheumatic heart disease. Geneva, Switzerland; 2001. Accessed October 23, 2020. https:\/\/apps.who.int\/iris\/handle\/10665\/42898"},{"key":"e_1_3_1_37_2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1081-1206(10)60305-5","article-title":"Allergy diagnostic testing: an updated practice parameter","volume":"100","author":"Bernstein IL","year":"2008","unstructured":"Bernstein IL, Li JT, Bernstein DI, Hamilton R, Spector SL, Tan R, Sicherer S, Golden DB, Khan DA, Nicklas RA, et al. Allergy diagnostic testing: an updated practice parameter. Ann Allergy Asthma Immunol. 2008;100:S1\u2013S148. doi: 10.1016\/S1081\u20101206(10)60305\u20105","journal-title":"Ann Allergy Asthma Immunol"},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.aller.2012.12.007"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.121.024517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T07:11:50Z","timestamp":1715584310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.121.024517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1161\/JAHA.121.024517"],"URL":"https:\/\/doi.org\/10.1161\/jaha.121.024517","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"2022-01-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e024517"}}